A5102821450- Cancer Genomics and Diagnostics
- Computational Drug Discovery Methods
- ATP Synthase and ATPases Research
- Genetics and Neurodevelopmental Disorders
- Pancreatic function and diabetes
- Genetics, Bioinformatics, and Biomedical Research
- Pancreatic and Hepatic Oncology Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetic Neurodegenerative Diseases
- Neurological disorders and treatments
- Ferroptosis and cancer prognosis
- Alzheimer's disease research and treatments
- RNA modifications and cancer
- Bladder and Urothelial Cancer Treatments
- Nerve injury and regeneration
- Gene expression and cancer classification
- Biotechnology and Related Fields
- Bioinformatics and Genomic Networks
- Cell Image Analysis Techniques
- Mitochondrial Function and Pathology
- Cancer Diagnosis and Treatment
- Vitamin C and Antioxidants Research
- Bioactive Compounds and Antitumor Agents
- Pharmaceutical Economics and Policy
IDEO (United States)
2024
Alleo Labs (United States)
2024
Immuneering (United States)
2015-2020
Massachusetts Institute of Technology
2015
Abstract Background The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease-2019 (COVID-19). Methods We applied two computational approaches identify potential therapeutics. First, we sought existing FDA approved that could block coronaviruses from entering cells binding ACE2 TMPRSS2 using high-throughput AI-based affinity prediction...
Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints clinical trials. Originally described a dopamine stabilizer, this mechanism is insufficient to explain the and preclinical effects of pridopidine. This study therefore explored pridopidine's potential mechanisms action. The effect pridopidine versus sham treatment on genome-wide expression profiling rat striatum was analysed compared pathological profile Q175 knock-in (Q175...
Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. was administered either prior the appearance phenotypes or in advanced stages YAC128 mouse model HD. In early treatment cohort, animals received 0, 10, 30 mg/kg pridopidine a period 10.5 months. late were treated 8 weeks 0 an escalating dose (10 over 3 weeks). Early improved motor coordination reduced anxiety-...
Huntington Disease (HD) is an incurable autosomal dominant neurodegenerative disorder driven by expansion repeat giving rise to the mutant huntingtin protein (mHtt), which known disrupt a multitude of transcriptional pathways. Pridopidine, small molecule in development for treatment HD, has been shown improve motor symptoms HD patients. In animal models, pridopidine exerts neuroprotective effects and improves behavioral functions. Pridopidine binds primarily sigma-1 receptor, (IC50 ~ 100...
The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease – 2019 (COVID-19). We applied two computational approaches identify potential therapeutics. First, we sought existing FDA approved that could block coronaviruses from entering cells binding ACE2 TMPRSS2 using high-throughput AI-based affinity prediction platform. Top results included...
Abstract Huntington disease (HD) is a hereditary neurodegenerative disorder caused by mutant huntingtin (mHTT). Phosphorylation at serine-421 (pS421) of mHTT has been shown to be neuroprotective in cellular and rodent models. However, the genetic context these models differs from that HD patients. Here we employed human pluripotent stem cells (hiPSCs), which express endogenous full-length mHTT. Using genome editing, generated isogenic hiPSC lines S421 site mutated into phospho-mimetic...
Recent advances in machine learning hold tremendous potential for enhancing the way we develop new medicines. Over years, has been adopted nearly all facets of drug discovery, including patient stratification, lead biomarker development, and clinical trial design. In this review, will discuss latest developments linking CNS discovery. While aided our understanding chronic diseases like Alzheimer’s disease Parkinson’s disease, only modest effective therapies currently exist. We highlight...
<p>The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease – 2019 (COVID-19). We applied two computational approaches identify potential therapeutics. First, we sought existing FDA approved that could block coronaviruses from entering cells binding ACE2 TMPRSS2 using high-throughput AI-based affinity prediction platform. Top results...
Abstract Background Insulin‐like Growth Factor‐1 (IGF‐1) and its receptor (IGF‐1R) are known to play a role in biological aging. Several studies have explored the correlation between serum levels of IGF‐1 Alzheimer's‐related dementia (AD). However, conflicting reports exist regarding whether elevated or reduced increase risk AD. The focus this study is investigate relationship AD participates Alzheimer’s Disease Neuroimaging Initiative (ADNI) study. Methods We analyzed calculated readouts...
<h3>Background</h3> COVID-19 is a global public health crisis with no effective therapeutic strategies or vaccines available. The disease caused by the SARS-CoV-2 virus, novel coronavirus that enters cells through ACE2 receptor. To rapidly identify existing drugs might preferentially bind to receptor we sought use an artificial intelligence platform evaluate ~3,000 known in FDA approved drug library (Selleckchem). <h3>Methods</h3> Fluency quantitative structure–activity relationship (QSAR)...
April 25, 2018April 10, 2018Free AccessLoss of the Sigma-1 receptor disrupts pridopidine-induced gene expression (P4.048)Jennifer Dreymann, Michal Geva, Jermaine Ross, Yoonjeong Cha, Rebecca Kusko, Renan Escalante-Chong, Ben Zeskind, Daphna Laifenfeld, Iris Grossman, and Michael HaydenAuthors Info & AffiliationsApril 2018 issue90 (15_supplement) Letters to Editor
<h3>Background</h3> Uveal melanoma is a rare variant of associated with monosomy 3, present high risk for metastatic disease, and has been resistant to all therapeutic approaches. We sought use novel advanced big data approach identify potential new immunotherapy targets the treatment uveal melanoma. <h3>Methods</h3> Comprehensive multiplatform analysis 80 primary specimens in TCGA gene expression database were evaluated. There four previously reported [Robertson <i>et al</i>, Cancer Cell,...
Abstract Cell lines used for pre-clinical testing of oncology compounds are not always chosen based on how well they models patient tumors. Instead often availability and literature prevalence. The advent high throughput genomic profiling demonstrates a causative relationship between features drug response, suggesting that cancer discovery could be accelerated by using genomics as criteria to find ideal cell given type. overall clinical trial success rate is dismally low, especially in...
Abstract Cancer cell lines represent the front line of new compound testing, and results from these experiments often decide which compounds go on for further testing. Genomic context plays a critical role in drug response now genomic data tumors are widely available. However, chosen based ease access, literature prevalence, culture. We combined gene expression CNV/mutation profiling four pancreatic cancer tumor datasets (GSE21501, GSE28735, ICGC, TCGA,) three (Klijn et al, Collisson CCLE)...
Abstract Currently, pancreatic cancer has an estimated 5-year survival rate of only 5-6%. The projection that will be the second leading cause related death by 2020 compounded numerous clinical trial failures precipitates need for novel approaches to accelerate progress in new medicine development. Cell lines used screening pre-clinical compounds prior animal models and human testing are usually chosen based on ease access literature prevalence. However, constellation genomic derangements...
e15268 Background: Despite substantial research efforts in pancreatic cancer the estimated 5-year survival rate remains 5-6%. The lack of early detection methods compounded by a startlingly low clinical trial success precipitates need for innovative approaches to drug development. Choice cell lines used pre-clinical compound screening is usually based on ease culture, popularity, and availability. However, we have observed that constellation pathway derangements commonly may not optimally...
e15730 Background: Pancreatic cancer has an estimated 5-year survival rate of only 5-6% and is often diagnosed after metastasis occurred. Gemcitabine or gemcitabine combination therapies are frequently utilized, although existing highly toxic. The minimal effectiveness current treatment options for pancreatic precipitates the urgent unmet clinical need promising novel to enhance efficacy gemcitabine. Methods: In order interrogate targetable mechanisms which orchestrate resistance, we...
Abstract Introduction: Targeting metastasis has the potential to reduce lethality of cancer, instead making it a manageable disease. While been studied extensively in individual forms less attention paid aspects metastatic progression conserved across cancers. Here, we identify mechanisms consistently associated with primary tumors from 4106 patients 12 different cancers via comparison primary-site no lymph node involvement those staging other tissues or nodes. Methods: Leveraging RNA-seq...